SLEDAI-2K

Check each descriptor that represents active SLE attributable to lupus in the prior 4 weeks, using SLEDAI-2K definitions. Sum weighted points (maximum 105).

Total score

0 / 105

No SLEDAI-2K activity (0)

A score of 0 indicates no descriptors met. Clinical “remission” definitions often integrate PGA, medications, and organ-specific targets—not SLEDAI-2K alone.

Disclaimer: This tool sums published SLEDAI-2K weights only. Descriptor attribution, infection vs flare, medication effects, and lab timing require clinical judgment. It does not replace rheumatology assessment or trial-specific remission definitions.

SLEDAI-2K — scoring and context

What changed from SLEDAI to SLEDAI-2K?

Weights and the 24 descriptors are the same as the original SLEDAI. SLEDAI-2K attributes activity if it was present over the previous 4 weeks, and revises several items so that persistent activity (e.g., rash, mucosal ulcers, alopecia, proteinuria, urinary sediment findings, arthritis, serositis, fever, cytopenias) can score when still active—not only when “new” compared with a prior visit. Primary references: Gladman DD et al., J Rheumatol 2002;29(2):288–291; Yee CS et al., Rheumatology (Oxford) 2005;44(3):401–405.

Weighted descriptors

Each line is scored once if the descriptor is met per SLEDAI-2K rules. Maximum total = 105.

Descriptor	Points
Seizure	8
Psychosis	8
Organic brain syndrome	8
Visual disturbance	8
Cranial nerve disorder	8
Lupus headache (severe, persistent; responsive to narcotics only)	8
Cerebrovascular accident (CVA)	8
Vasculitis	8
Arthritis	4
Myositis	4
Urinary casts (hemoglobin or granular)	4
Hematuria (>5 RBC/HPF)	4
Proteinuria (>0.5 g/24 h or >3+ if not quantified)	4
Pyuria (>5 WBC/HPF, excluding infection)	4
Active lupus rash	2
Alopecia (active, abnormal)	2
Mucosal ulcers	2
Pleurisy (with rub or effusion, or pleuritic pain)	2
Pericarditis (with rub, effusion, ECG, or echo evidence)	2
Low complement (C3 or C4 below lab LLN)	2
Increased anti-dsDNA (above lab ULN or >25% above baseline if known)	2
Fever (>38°C, excluding infection)	1
Thrombocytopenia (<100 × 10⁹/L)	1
Leukopenia (<3.0 × 10⁹/L, excluding drug cause)	1

Activity bands in this calculator

The bands below are educational summaries used in many teaching materials; they are not a single official international standard for “mild” vs “moderate” lupus. Trials and guidelines may use different cutoffs or combine SLEDAI-2K with other measures.

0 — no descriptors
1–5 — mild
6–10 — moderate
11–19 — high
≥20 — very high / severe flare range

What SLEDAI-2K measures

The Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) is a clinician-oriented index that quantifies global SLE activity by assigning weighted points to 24 descriptors spanning neurologic, mucocutaneous, musculoskeletal, renal, serosal, constitutional, hematologic, and immunologic domains. The index is intended to summarize whether lupus is quiescent, partially active, or substantially active over a defined recent interval, so that changes on repeat scoring can be interpreted in the context of treatment, comorbidity, and organ-specific targets.

Operationally, SLEDAI-2K is a checklist with fixed weights: each descriptor is either present and attributable to SLE within the scoring window (and therefore contributes its full point value) or absent (0 points). The total score is the simple sum of all positive descriptors. The theoretical maximum is 105, achieved only if every descriptor is simultaneously met, which is uncommon in practice.

Historical context: from SLEDAI to SLEDAI-2K

The original SLEDAI was developed to standardize disease activity measurement for clinical research and longitudinal care. A practical limitation emerged for several descriptors that were framed in terms of “new” or “recurrent” manifestations compared with a prior assessment. In real clinics, patients often return with persistent rashes, oral or nasal ulcers, ongoing proteinuria, chronic cytopenias, continued arthritis, or sustained serologic perturbations. Under strict “newness” wording, those findings could be under-scored even when they still represented meaningful active disease.

SLEDAI-2K retained the same 24 items and the same weights as SLEDAI but revised attribution rules so that ongoing activity within the index window could score for selected descriptors when still clinically active, aligning the instrument with how rheumatologists judge flare and response outside of strictly incident events. The revision aimed to improve face validity and sensitivity to persistent activity without changing the overall structure that trials and cohorts had already adopted.

Scoring window and attribution

SLEDAI-2K is anchored to a recent observation period, commonly described as approximately the prior four weeks (or the month preceding the visit). The clinician (or trained assessor) determines whether each descriptor is present and active during that interval and, critically, whether it is reasonably attributed to SLE rather than to an alternative explanation.

Attribution is not automatic. Many SLEDAI-2K items overlap with findings seen in infection, medication toxicity, metabolic disturbances, or non-lupus organ disease. For example, fever, cytopenias, serositis, neuropsychiatric symptoms, urinary sediment abnormalities, and rash can each have non-lupus causes. The index assumes disciplined clinical judgment: items should be checked only when the feature is clinically convincing for lupus activity after a reasonable competing-workup lens—without implying that every center uses identical thresholds.

How weights are assigned across organ systems

The 24 descriptors use a simple tiered weighting scheme that reflects the relative severity and clinical impact associated with each manifestation in the original instrument design.

Eight points are assigned to major neurologic and high-impact vascular-inflammatory manifestations (for example, seizure, psychosis, organic brain syndrome, certain visual and cranial nerve syndromes, severe lupus headache as defined by the instrument, stroke/cerebrovascular accident in the SLE context, and vasculitis).
Four points are assigned to substantial inflammatory musculoskeletal disease (arthritis, myositis) and to selected renal laboratory markers of active lupus nephritis activity (including urinary casts, hematuria, proteinuria, and pyuria when meeting instrument definitions and not better explained by infection alone).
Two points are assigned to mucocutaneous and serosal features (active rash, alopecia judged active and abnormal for the patient, mucosal ulcers, pleurisy, pericarditis) and to key immunologic laboratory activity markers such as low complement and increased anti–double-stranded DNA binding by the instrument’s rules.
One point is assigned to constitutional and cytopenic markers (fever meeting the instrument’s temperature and exclusion assumptions, thrombocytopenia, leukopenia) when attributable to SLE and not solely explained by drugs or alternate disease.

Because the score is a sum of independent items, patients with multi-organ involvement can accumulate points quickly; conversely, a patient may have severe single-organ disease that is only partially reflected if the chosen descriptors do not capture that organ’s unique presentation.

Laboratory integration: complements and anti-dsDNA

SLEDAI-2K includes immunologic activity as measurable endpoints. Low C3 and/or C4 relative to the laboratory reference range is scored as a discrete two-point item when interpreted as active immunologic complement consumption in the clinical context. Anti-dsDNA activity is scored when thresholds defined by the instrument are met, often framed relative to the laboratory upper limit of normal and/or a clinically relevant rise from a known baseline in patients where serial serology is tracked.

Serologic changes should be integrated with the rest of the phenotype: some patients have discordance between serology and clinical activity, and some therapeutic strategies intentionally target antibodies or complement without implying that every lab shift equals a flare.

Renal descriptors and urinary findings

The renal items capture active urine sediment and proteinuria patterns associated with lupus nephritis activity using instrument-specified cutoffs (including thresholds for red cells, white cells, casts, and protein excretion or dipstick equivalents when quantification is unavailable). These items are among the highest leverage contributors to the total score when active nephritis is present, which matches the clinical reality that kidney involvement drives both morbidity and urgency.

Practical pitfalls include contamination, infection, menstrual blood, catheter-related findings, and non-lupus glomerular disease. The index does not replace urinalysis interpretation by a nephrologist or the need for biopsy correlation when diagnosis, class, or chronicity remains uncertain.

Neuropsychiatric items: high weight, high responsibility

The eight-point neurologic descriptors reflect the outsized morbidity risk associated with neuropsychiatric SLE syndromes. These items demand careful differentiation from primary psychiatric illness, substance effects, metabolic encephalopathy, sepsis, posterior reversible encephalopathy syndrome, and other cerebrovascular events unrelated to SLE. Misclassification can both inflate the score and distract from emergent non-lupus conditions.

Using totals in clinical practice and research

In many educational materials, total SLEDAI-2K scores are loosely grouped into broad bands (for example, very low scores versus higher scores suggesting more active global disease). These bands are not universally standardized across every trial, registry, or guideline; some definitions of remission or low disease activity incorporate SLEDAI-2K together with other measures (such as physician global assessment, medication allowance, and organ-specific criteria).

Where SLEDAI-2K excels is longitudinal tracking: comparing a patient’s score at two time points after a therapy change, during tapering, or during pregnancy monitoring. A rising total may prompt reconsideration of adherence, infection, medication withdrawal, or true flare; a falling total supports response, though it must be read alongside fixed deficits (damage) that may persist even when activity improves.

Limitations clinicians should keep in mind

SLEDAI-2K is a global activity gauge, not a complete substitute for organ-specific staging (for example, detailed lupus nephritis class activity on biopsy, neuroimaging correlates, or cutaneous subsets). It does not directly measure damage (irreversible scarring or chronic impairment), which is often captured by separate instruments. It also does not encode every rare manifestation of SLE; unusual presentations may be clinically important yet poorly represented.

Inter-rater variability can occur when centers differ in how aggressively they attribute ambiguous findings to lupus versus alternative causes. Training, standardized data collection forms, and explicit local rules for borderline labs can improve consistency in multidisciplinary settings.

How this calculator should be used on CalcMD

This calculator is designed to apply the published weights to a user-selected set of descriptors and display a running total. It supports education, documentation rehearsal, and quick arithmetic checking. It does not independently verify attribution, exclude infection, adjudicate laboratory methodology, or replace specialist judgment. Any clinical decision—especially for immunosuppression intensity, anticoagulation in the setting of thrombocytopenia, or evaluation of neuropsychiatric symptoms—must remain individualized and guideline-directed.

CalcMD.

Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K)

Learn how SLEDAI-2K measures SLE activity over the prior month: 24 weighted descriptors (max 105), SLEDAI-2K vs SLEDAI, attribution, organ systems, labs, and how totals are used in care and trials.